Research programme: gene-activated follicle-stimulating hormone - Shire

Drug Profile

Research programme: gene-activated follicle-stimulating hormone - Shire

Alternative Names: Follicle-stimulating hormone - Shire; FSH - Shire; GA-FSH; Gene-activated follicle-stimulating hormone; Gene-activated FSH

Latest Information Update: 10 May 2006

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Shire Pharmaceuticals Group
  • Class Follicle stimulating hormones; Pituitary gonadotropins
  • Mechanism of Action Ovarian follicle stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Female infertility

Most Recent Events

  • 10 May 2006 Discontinued - Preclinical for Female infertility in USA (Parenteral)
  • 28 Jul 2005 Transkaryotic Therapies has been acquired and merged into Shire Pharmaceuticals Group
  • 23 Aug 2004 Transkaryotic Therapies is seeking partnership opportunities for this research programme (http://www.transkaryotictherapies.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top